A research team in Korea has developed a vaccine technology that delivers long-lasting immune protection from a single dose ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad population the company had originally sought. The FDA has approved Novavax’s shot, ...

Researchers developed a mussel-inspired adhesive adjuvant that anchors antigens and prolongs release. It enhanced T-cell ...

One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and antibodies. In most vaccines, HIV proteins are attached to a larger protein ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A supercharged HIV vaccine could offer strong protection with just one ...

One of the biggest hurdles in developing an HIV vaccine is coaxing the body to produce the right kind of immune cells and antibodies. In most vaccines, HIV proteins are attached to a larger protein ...

Researchers at Oregon Health & Science University have found a key to developing a vaccine against one of humankind’s oldest ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, noted ...

The vaccine, intended for people 50 and older, is based on mRNA technology and was found in an advanced trial to be more ...

The DNA-based vaccine induces antibodies to the HIV antigen (blue) without eliciting antibodies to the DNA particle (gray), whereas the protein-based vaccine generates antibodies to both the HIV ...